The New England journal of medicine, 2018-03, Vol.378 (13), p.1200-1210
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
- Ist Teil von
- The New England journal of medicine, 2018-03, Vol.378 (13), p.1200-1210
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2018
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Patients with gout and cardiovascular disease were assigned to receive febuxostat or allopurinol. At 32 months, there was no significant between-group difference in a composite cardiovascular end point, but all-cause and cardiovascular mortality were higher with febuxostat.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1710895Titel-ID: cdi_proquest_journals_2024553515
- Format
- –
- Schlagworte
- Aged, Allopurinol, Allopurinol - adverse effects, Allopurinol - therapeutic use, Angina, Angina pectoris, Cardiovascular disease, Cardiovascular diseases, Cardiovascular Diseases - chemically induced, Cardiovascular Diseases - complications, Cardiovascular Diseases - mortality, Cause of Death, Cerebral infarction, Chronic illnesses, Clinical trials, Death, Double-Blind Method, Drug dosages, Evidence-based medicine, Febuxostat - adverse effects, Febuxostat - therapeutic use, Female, Gout, Gout - complications, Gout - drug therapy, Gout Suppressants - adverse effects, Gout Suppressants - therapeutic use, Heart attacks, Heart failure, Humans, Male, Medicine, Metabolism, Middle Aged, Mortality, Motivation, Myocardial infarction, Patients, Rheumatism, Xanthine oxidase